Metsera, Inc. Announces Promising Results from Phase 2b Trials
Metsera, Inc. (Nasdaq: MTSR) has revealed encouraging preliminary findings from its VESPER-1 and VESPER-3 trials, both Phase 2b studies evaluating MET-097i, a pioneering GLP-1 receptor agonist designed for extended use. The data indicates a mean placebo-adjusted weight reduction of up to 14.1% after 28 weeks of treatment, with no evidence of a plateau in weight loss observed.
Exceptional Tolerability and Retention Rates
The trials exhibited a strong potential for tolerability, with minimal reports of diarrhea, 13% incidence of nausea, and 11% vomiting among participants receiving the highest dose in VESPER-3. Notably, retention rates during both trials were high, highlighting the feasibility of MET-097i as a treatment option.
Advancement to Phase 3 Trials Expected by Late 2025
Steve Marso, M.D., Chief Medical Officer of Metsera, emphasized the significance of the findings, stating that MET-097i shows promise as a leading ultra-long-acting hormone analog, offering competitive efficacy and superior convenience. With a discontinuation rate of just 2.9% in VESPER-1, the data supports the transition to Phase 3 clinical trials, anticipated to commence in late 2025.
Study Design and Participant Demographics
The VESPER-1 and VESPER-3 trials involved overweight or obese individuals without type 2 diabetes. In VESPER-1, 239 participants received doses from 0.4 mg to 1.2 mg weekly for 28 weeks. The ongoing VESPER-3 trial has enrolled 268 subjects and is designed to assess the efficacy and tolerability of various monthly doses of MET-097i.
Weight Loss Results and Analysis
In VESPER-1, the weight loss observed was dose-dependent, achieving a maximum placebo-adjusted mean of 14.1% at the highest dosage of 1.2 mg. Individual responses varied significantly, with some participants experiencing weight loss as high as 26.5%. Further analyses demonstrated that substantial weight loss continued past the 28-week mark, indicating ongoing efficacy.
Notable Tolerability Observations
Tolerability results for MET-097i were favorable, with a starting dose of 0.4 mg showing side effects comparable to placebo across various doses in both trials. Specifically, the VESPER-3 trial indicated minimal gastrointestinal disturbances, affirming the potential for superior tolerability with the titration approach.
High Participant Retention Rates
The VESPER-1 trial reported a low total discontinuation rate of 2.9%, with only two participants withdrawing due to adverse effects. The VESPER-3 trial maintains a high retention rate as it progresses.
Confirmation of Phase 3 Dosing Regimens
The clear dose-response relationship for weight loss in VESPER-1, along with improved tolerability from the titration strategies evaluated in VESPER-3, has led Metsera to finalize dosing regimens for Phase 3 trials. The company is optimistic that MET-097i can achieve performance metrics comparable to existing market leaders at significantly lower doses and with fewer required titration steps.
Expert Commentary on MET-097i
Professor John B. Buse, M.D., Ph.D., highlighted the trial results, underscoring MET-097i’s efficacy and tolerability. He noted the potential for monthly dosing, which could significantly enhance treatment accessibility for individuals requiring hormone therapies for obesity management. He stressed that any new treatment in this space must meet or surpass the benchmarks set by current options, such as tirzepatide.
Future Developments and Ongoing Trials
Encouraged by the positive topline data, Metsera is set to launch a global Phase 3 program in late 2025. Ongoing Phase 2b trials will continue to assess MET-097i’s long-term effects and its efficacy in patients with type 2 diabetes. The company is also pursuing multiple additional clinical programs involving MET-097i and its combinations.
About MET-097i
MET-097i represents a fully biased, ultra-long-acting GLP-1 receptor agonist intended for monthly administration, showcasing exceptional potency and compatibility with other Metsera analogs. The development aims for regulatory approval in the U.S. through the FDA’s biologic pathway.
Metsera’s Innovative HALO™ Platform
Metsera employs its HALO™ platform to stabilize peptides, allowing them to bind effectively to both albumin and their target sites. This innovative approach is designed to extend the half-life of peptides, potentially facilitating monthly dosing and improved patient tolerability.
About Metsera, Inc.
As a clinical-stage biopharmaceutical entity, Metsera is pioneering next-generation treatments for obesity and metabolic disorders. The company is committed to developing a comprehensive range of oral and injectable therapies designed to meet the evolving needs of weight management solutions. Established in 2022, Metsera is headquartered in New York City.
Forward-Looking Statements
This announcement includes forward-looking statements regarding Metsera’s clinical programs and business strategies, which are subject to various risks and uncertainties that may lead to actual outcomes differing from those projected. Interested parties are encouraged to review the detailed risks outlined in Metsera’s regulatory filings.
